- Home
- SPRO vs GRWG Comparison
SPRO vs GRWG Comparison
Compare SPRO & GRWG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- GRWG
- Stock Information
- Founded
- SPRO 2013
- GRWG 2008
- Country
- SPRO United States
- GRWG United States
- Employees
- SPRO N/A
- GRWG N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- GRWG RETAIL: Building Materials
- Sector
- SPRO Health Care
- GRWG Consumer Discretionary
- Exchange
- SPRO Nasdaq
- GRWG Nasdaq
- Market Cap
- SPRO 110.9M
- GRWG 98.0M
- IPO Year
- SPRO 2017
- GRWG N/A
- Fundamental
- Price
- SPRO $2.13
- GRWG $1.77
- Analyst Decision
- SPRO Buy
- GRWG Strong Buy
- Analyst Count
- SPRO 4
- GRWG 1
- Target Price
- SPRO $5.00
- GRWG $2.50
- AVG Volume (30 Days)
- SPRO 308.6K
- GRWG 712.2K
- Earning Date
- SPRO 11-13-2025
- GRWG 11-11-2025
- Dividend Yield
- SPRO N/A
- GRWG N/A
- EPS Growth
- SPRO N/A
- GRWG N/A
- EPS
- SPRO N/A
- GRWG N/A
- Revenue
- SPRO $48,576,000.00
- GRWG $164,108,000.00
- Revenue This Year
- SPRO N/A
- GRWG N/A
- Revenue Next Year
- SPRO N/A
- GRWG N/A
- P/E Ratio
- SPRO N/A
- GRWG N/A
- Revenue Growth
- SPRO N/A
- GRWG N/A
- 52 Week Low
- SPRO $0.51
- GRWG $0.82
- 52 Week High
- SPRO $3.22
- GRWG $2.25
- Technical
- Relative Strength Index (RSI)
- SPRO 60.07
- GRWG 54.90
- Support Level
- SPRO $1.84
- GRWG $1.74
- Resistance Level
- SPRO $2.05
- GRWG $2.09
- Average True Range (ATR)
- SPRO 0.08
- GRWG 0.14
- MACD
- SPRO 0.03
- GRWG -0.02
- Stochastic Oscillator
- SPRO 85.71
- GRWG 37.74
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About GRWG GrowGeneration Corp.
GrowGeneration Corp owns and operates specialty retail hydroponic and organic gardening stores. The firm is a marketer and distributor of nutrients, growing media, indoor and greenhouse lighting, ventilation systems and accessories for hydroponic gardening. The Company has two reportable segments, including Cultivation and Gardening segment, composed of the Company's hydroponic and organic gardening business; and the Storage Solutions segment, composed of the Company's benching, racking, and storage solutions business.